From: Development and evaluation of a community-based buprenorphine treatment intervention
Method | Content description | Evaluation |
---|---|---|
Component 1: Buprenorphine Educationa | ||
Slide presentation | 8 modules: introduction; background information on buprenorphine; what is buprenorphine; who can take buprenorphine; getting on buprenorphine; buprenorphine and the brain; buprenorphine/naloxone vs. buprenorphine alone; effectiveness and safety of buprenorphine; being involved in your buprenorphine treatment | Mean satisfactionb = 1.9 Pre-post knowledge increased from 50 to 79% of answers correct.c |
Frequently asked questions | 30 questions frequently asked by people seeking buprenorphine treatment | |
Resource guide | Resources (websites and phone numbers) that provide buprenorphine information and list buprenorphine-prescribing physicians | |
Glossary of terms | 42 frequently used terms associated with opioid addiction and buprenorphine | |
Myths and facts about buprenorphine | 16 commonly held myths regarding buprenorphine, and the facts regarding these statements | |
Component 2: Motivational Interviewingd | ||
Slide presentation | Components: what is motivational interviewing; stages of change; key principles of motivational interviewing | Mean satisfactione = 4.5 |
Workbook | Self-reflection activities, stages of change clinical scenarios, role-playing activities | |
Component 3: Facilitate access to buprenorphine-prescribing physicians | ||
Identification of buprenorphine-prescribing physicians | Interactive exercises using websites to locate buprenorphine-prescribing physicians | Mean satisfactionb = 1.6 |
Facilitate clients’ accessing buprenorphine treatment | Role play phone calls to doctors’ offices inquiring about buprenorphine treatment; exploration of process to initiate buprenorphine treatment; role play potential structural barriers (insurance issues, medication cost, transportation) | |
Component 4: Support during buprenorphine treatment | ||
Case scenarios with common treatment challenges | Group discussion of 4 case scenarios that represent common treatment challenges: use of illicit buprenorphine; relapse; polysubstance use; severe untreated mental illness. | Mean satisfactionb = 1.6 |